Literature DB >> 11438248

Restless Legs Syndrome: scoring criteria for leg movements recorded during the suggested immobilization test.

M Michaud1, G Poirier, G Lavigne, J Montplaisir.   

Abstract

Objective: To evaluate the characteristics of leg movements experienced by patients with the restless legs syndrome (RLS) during wakefulness using the suggested immobilization test (SIT).
Methods: Forty patients with primary RLS who showed an index of leg movements greater than 40 during the SIT were selected for these analyses.
Results: In general, Coleman's criteria for scoring PLMS were appropriate for scoring leg movements during the SIT. However, a substantial number of leg movements lasted between 5 and 10 s, exceeding Coleman's maximum duration criterion. The other criteria used to score PLMS (i.e. movements separated by 4-90 s and occurring in series of four consecutive movements) allowed detection of more than 90% of all leg movements recorded during the SIT. The distribution of inter-movement intervals (IMI) suggests that a great majority of leg movements recorded during the SIT are periodic, with a modal value of IMI between 11-12 s.
Conclusion: Considering that leg movements recorded during the SIT last longer than those occurring during sleep, we recommend using a duration criterion of 0.5-10 s for scoring the former. We also recommend using the same periodicity criteria for the SIT as those used for scoring PLMS.

Entities:  

Year:  2001        PMID: 11438248     DOI: 10.1016/s1389-9457(00)00072-1

Source DB:  PubMed          Journal:  Sleep Med        ISSN: 1389-9457            Impact factor:   3.492


  9 in total

1.  A randomized, double-blind, placebo-controlled trial of intravenous iron sucrose in restless legs syndrome.

Authors:  Christopher J Earley; Alena Horská; Mona A Mohamed; Peter B Barker; John L Beard; Richard P Allen
Journal:  Sleep Med       Date:  2008-02-14       Impact factor: 3.492

2.  Recent advances in the diagnosis, genetics and treatment of restless legs syndrome.

Authors:  Claudia Trenkwalder; Birgit Högl; Juliane Winkelmann
Journal:  J Neurol       Date:  2009-04-27       Impact factor: 4.849

Review 3.  [Neurophysiological and neuroimaging studies for restless legs syndrome and periodic leg movement disorder].

Authors:  S Happe; W Paulus
Journal:  Nervenarzt       Date:  2006-06       Impact factor: 1.214

4.  Apomorphine in idiopathic restless legs syndrome: an exploratory study.

Authors:  G G Tribl; T Sycha; N Kotzailias; J Zeitlhofer; E Auff
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-02       Impact factor: 10.154

Review 5.  Restless legs syndrome: a sensorimotor disorder of sleep/wake motor regulation.

Authors:  Wayne A Hening
Journal:  Curr Neurol Neurosci Rep       Date:  2002-03       Impact factor: 5.081

6.  Periodic Limb Movements while Awake (PLMA) as a Manifestation of Wearing-Off in Parkinson's Disease: A Case Series and Review of the Literature.

Authors:  Sohaila Alshimemeri; Daniel G Di Luca; Diana A Olszewska; Eoin Mulroy; Kailash P Bhatia; Susan H Fox; Anthony E Lang
Journal:  Mov Disord Clin Pract       Date:  2022-06-10

7.  Defining the boundaries of the response of sleep leg movements to a single dose of dopamine agonist.

Authors:  Mauro Manconi; Raffaele Ferri; Thom R Feroah; Marco Zucconi; Luigi Ferini-Strambi
Journal:  Sleep       Date:  2008-09       Impact factor: 5.849

8.  Algorithms for the diagnosis and treatment of restless legs syndrome in primary care.

Authors:  Diego Garcia-Borreguero; Paul Stillman; Heike Benes; Heiner Buschmann; K Ray Chaudhuri; Victor M Gonzalez Rodríguez; Birgit Högl; Ralf Kohnen; Giorgio Carlo Monti; Karin Stiasny-Kolster; Claudia Trenkwalder; Anne-Marie Williams; Marco Zucconi
Journal:  BMC Neurol       Date:  2011-02-27       Impact factor: 2.474

9.  Validity and reliability of the suggested immobilization test for measurement of restless legs syndrome severity in adults with multiple sclerosis.

Authors:  Katie L J Cederberg; Arthur S Walters; Amy W Amara; Tiffany J Braley; Morgan L Schuetz; Brianna G Mathison; Robert W Motl
Journal:  Sleep Med       Date:  2021-06-16       Impact factor: 4.842

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.